RoyStrowdIIIMDMEd, MS

Neurooncology

Associate Professor Department of Neurology Department of Internal Medicine, Section on Hematology and Oncology Department of Clinical and Translational Sciences

Join to view full profile

Dr. Strowd is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Strowd's full profile

Already have an account?

Office
Medical Center Blvd
Winston Salem, NC 27157
Phone+1 336-716-7548

Summary

Dr. Roy Strowd is a neurologist and Neuro-Oncologist in Winston Salem, NC and is affiliated with Wake Forest Baptist Medical Center. He received his medical degree from Wake Forest School of Medicine, fellowship training at Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center and has been in practice 4 years. He specializes in neuro-oncology and is experienced in treating patients with primary brain tumors, cancer syndromes like neurofibromatosis, tuberous sclerosis, and neurological complications of cancer.

Education & Training

Johns Hopkins School of EducationMEd, Health Professions Education, 2014 - 2018
Johns Hopkins UniversityFellowship, Neuro-Oncology, 2013 - 2015
Wake Forest University Baptist Medical CenterChief Residency, Neurology, 2012 - 2013
Wake Forest University Baptist Medical CenterResidency, Neurology, 2009 - 2013
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2009

Certifications & Licensure

NC State Medical License 2009 - 2024
MD State Medical License 2013 - 2015
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis Start of enrollment: 2015 May 01
Recruiting
Phase 2
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors Start of enrollment: 2016 May 01
Completed
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Start of enrollment: 2018 Jul 09
Recruiting
Phase 1
Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer Start of enrollment: 2017 May 11
Completed
Not Applicable
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07
Terminated
Phase 1
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Start of enrollment: 2019 Mar 13
Recruiting
Early Phase 1
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma Start of enrollment: 2021 Jan 27
Suspended
Phase 2
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma Start of enrollment: 2019 Nov 01
Terminated
Not Applicable
Social Determinants of Health in Glioblastoma Population Start of enrollment: 2019 May 22
Completed
Cereset for Caregivers Start of enrollment: 2024 Mar 01
Withdrawn
Not Applicable
Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy Start of enrollment: 2019 Dec 17
Recruiting
Not Applicable
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Start of enrollment: 2019 Nov 11
Recruiting
Join now to see all

Publications & Presentations

PubMed

12 citations
Usefulness of the measurement of neurite outgrowth of primary sensory neurons to study cancer-related painful complications.
Sun H. Park, Matthew R. Eber, Miriam M. Fonseca, Chirayu M Patel, Katharine Cunnane
Biochemical Pharmacology. 2021-06-01
11 citations
Education Research: Difficult conversations in neurology: Lessons learned from medical students.
Monica E. Lemmon, Charlene E. Gamaldo, Rachel E. Salas, Ankita Saxena, Tiana E. Cruz
Neurology. 2018-01-09
2 citations
A Review on the Surgical Management of Insular Gliomas.
Jaclyn J. Renfrow, Bao-Quynh Julian, Desmond A. Brown, Stephen Tatter, Adrian W. Laxton
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2021-10-29

Lectures

Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

How Does the Body Feel Pain? | Neuropathic PainFebruary 12th, 2023
Opioid Stewardship Training Empowers Medical Students to Address Addiction and Pain ManagementDecember 15th, 2021
One Major Effect the Keto Diet Has on Cancer, New Study SuggestsJuly 17th, 2021
Join now to see all